Antibiotics: Zyvoxam linked to neuropathy


Linezolid ( Zyvoxam ), a synthetic antibacterial agent in a new class of antibiotics, the oxazolidinones, has been marketed in Canada since 2001. Linezolid is active against methicillin- and vancomycin-resistant gram-positive microorganisms.

The safety and efficacy of Linezolid given for longer than 28 days have not been evaluated in controlled clinical trials. Dosage and administration guidelines recommend that treatment last no more than 28 consecutive days. Because of its activity against resistant organisms that cause osteomyelitis and prosthetic joint infections, linezolid has been used in clinical practice for longer than the recommended treatment course.

The long-term use of lLnezolid has been associated with severe peripheral and optic neuropathy. In most cases the optic neuropathy resolved after stopping the drug, but the peripheral neuropathy did not.

Health Canada has received a report of a 71-year-old woman who received linezolid, 600 mg twice daily, for an acquired methicillin-resistant Staphylococcus aureus (MRSA) infection. The patient received an initial 6-week course of linezolid, stopped treatment for 4–5 months and was given the drug again for 8 months. Linezolid was stopped when the patient was admitted to hospital with anemia, pure red cell aplasia and severe peripheral neuropathy. She had initially noticed numbness in her feet a month previously. At the time of the report, the anemia had resolved but the neuropathy had not. Novo-Hydrazide was also considered a suspect drug.

Neuropathy ( peripheral or optic ) has rarely been reported in patients treated with linezolid and has primarily occurred in patients treated for more than the maximum recommended duration of 28 days. Myelosuppression including anemia is listed in the product monograph under warnings and postmarketing experience. Pure red cell aplasia is not listed in the product monograph.

Health care professionals must be aware of the potential for serious adverse reactions, including neuropathy, when linezolid is used beyond its recommended duration.

Source : Health Canada, 2005

XagenaMedicine_2005


Indietro

Altri articoli

Fungal infections that are resistant to treatment are an emerging public health problem, but everyone has a role in preventing...


The U.S. Food and Drug Administration ( FDA ) has advised that the serious side effects associated with fluoroquinolone antibacterial...


Office of Orphan Products Development ( OOPD ) of the Food and Drug Administration ( FDA ) has granted orphan...


The FDA ( Food and Drug Administration ) has concluded that Doribax ( Doripenem ), an antibacterial drug that has...


The FDA ( Food and Drug Administration ) has approved Xtoro ( Finafloxacin otic suspension ), a new drug used...


The FDA ( Food and Drug Administration ) has approved Sivextro ( Tedizolid phosphate ), a new antibacterial drug, to...


Use of Nitrofurantoin for urinary tract infections is contraindicated in patients with less than 60 mL/min creatinine clearance. Healthcare professionals...


Chronic bacterial prostatitis ( CBP ) is frequently diagnosed in men of fertile age, and is characterized by a disabling...


The Food and Drug Administration ( FDA ) warned the public that Azithromycin ( Zithromax or Zmax ) can cause...


The FDA ( Food and Drug Administration ) has approved Altabax ( Retapamulin ointment ) for topical treatment of impetigo...